Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Erratum: Chen, L.X., et al. Synthesis and Structure of the Inclusion Complex {NdQ[5]K@Q[10](H₂O)₄}•4NO₃•20H₂O. Molecules 2017, 22, 1147.

Chen LX, Kan JL, Cong H, Prior TJ, Tao Z, Xiao X, Redshaw C.

Molecules. 2019 Jan 17;24(2). pii: E328. doi: 10.3390/molecules24020328.

2.

Pd NP-Loaded and Covalently Cross-Linked COF Membrane Microreactor for Aqueous CBs Dechlorination at Room Temperature.

Yao BJ, Li JT, Huang N, Kan JL, Qiao L, Ding LG, Li F, Dong YB.

ACS Appl Mater Interfaces. 2018 Jun 20;10(24):20448-20457. doi: 10.1021/acsami.8b04022. Epub 2018 Jun 8.

PMID:
29847916
3.

Surface Decorated Porphyrinic Nanoscale Metal-Organic Framework for Photodynamic Therapy.

Kan JL, Jiang Y, Xue A, Yu YH, Wang Q, Zhou Y, Dong YB.

Inorg Chem. 2018 May 7;57(9):5420-5428. doi: 10.1021/acs.inorgchem.8b00384. Epub 2018 Apr 17.

PMID:
29664624
4.

Ru Nanoparticles-Loaded Covalent Organic Framework for Solvent-Free One-Pot Tandem Reactions in Air.

Chen GJ, Li XB, Zhao CC, Ma HC, Kan JL, Xin YB, Chen CX, Dong YB.

Inorg Chem. 2018 Mar 5;57(5):2678-2685. doi: 10.1021/acs.inorgchem.7b03077. Epub 2018 Feb 12.

PMID:
29431429
5.

Binding and Selectivity of Essential Amino Acid Guests to the Inverted Cucurbit[7]uril Host.

Gao ZZ, Kan JL, Chen LX, Bai D, Wang HY, Tao Z, Xiao X.

ACS Omega. 2017 Sep 8;2(9):5633-5640. doi: 10.1021/acsomega.7b00429. eCollection 2017 Sep 30.

6.

Synthesis and Structure of the Inclusion Complex {NdQ[5]K@Q[10](H₂O)₄}·4NO₃·20H₂O.

Chen LX, Kan JL, Cong H, Prior TJ, Tao Z, Xiao X, Redshaw C.

Molecules. 2017 Jul 9;22(7). pii: E1147. doi: 10.3390/molecules22071147. Erratum in: Molecules. 2019 Jan 17;24(2):.

7.

Au@Cu(II)-MOF: Highly Efficient Bifunctional Heterogeneous Catalyst for Successive Oxidation-Condensation Reactions.

Wang JS, Jin FZ, Ma HC, Li XB, Liu MY, Kan JL, Chen GJ, Dong YB.

Inorg Chem. 2016 Jul 5;55(13):6685-91. doi: 10.1021/acs.inorgchem.6b00925. Epub 2016 Jun 20.

PMID:
27322613
8.

Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.

Belmont PJ, Jiang P, McKee TD, Xie T, Isaacson J, Baryla NE, Roper J, Sinnamon MJ, Lee NV, Kan JL, Guicherit O, Wouters BG, O'Brien CA, Shields D, Olson P, VanArsdale T, Weinrich SL, Rejto P, Christensen JG, Fantin VR, Hung KE, Martin ES.

Sci Signal. 2014 Nov 11;7(351):ra107. doi: 10.1126/scisignal.2005516.

PMID:
25389372
9.

Molecular predictors of sensitivity to the insulin-like growth factor 1 receptor inhibitor Figitumumab (CP-751,871).

Pavlicek A, Lira ME, Lee NV, Ching KA, Ye J, Cao J, Garza SJ, Hook KE, Ozeck M, Shi ST, Yuan J, Zheng X, Rejto PA, Kan JL, Christensen JG.

Mol Cancer Ther. 2013 Dec;12(12):2929-39. doi: 10.1158/1535-7163.MCT-13-0442-T. Epub 2013 Oct 9.

10.

Tumor P-Glycoprotein Correlates with Efficacy of PF-3758309 in in vitro and in vivo Models of Colorectal Cancer.

Bradshaw-Pierce EL, Pitts TM, Tan AC, McPhillips K, West M, Gustafson DL, Halsey C, Nguyen L, Lee NV, Kan JL, Murray BW, Eckhardt SG.

Front Pharmacol. 2013 Mar 22;4:22. doi: 10.3389/fphar.2013.00022. eCollection 2013.

11.

Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation.

Martin ES, Belmont PJ, Sinnamon MJ, Richard LG, Yuan J, Coffee EM, Roper J, Lee L, Heidari P, Lunt SY, Goel G, Ji X, Xie Z, Xie T, Lamb J, Weinrich SL, VanArsdale T, Bronson RT, Xavier RJ, Vander Heiden MG, Kan JL, Mahmood U, Hung KE.

Clin Cancer Res. 2013 Jun 1;19(11):2929-40. doi: 10.1158/1078-0432.CCR-12-2307. Epub 2013 Feb 12.

12.

Combination of a MEK inhibitor at sub-MTD with a PI3K/mTOR inhibitor significantly suppresses growth of lung adenocarcinoma tumors in Kras(G12D-LSL) mice.

Simmons BH, Lee JH, Lalwani K, Giddabasappa A, Snider BA, Wong A, Lappin PB, Eswaraka J, Kan JL, Christensen JG, Shojaei F.

Cancer Chemother Pharmacol. 2012 Aug;70(2):213-20. doi: 10.1007/s00280-012-1899-6. Epub 2012 Jun 9.

PMID:
22684718
13.

An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.

Hook KE, Garza SJ, Lira ME, Ching KA, Lee NV, Cao J, Yuan J, Ye J, Ozeck M, Shi ST, Zheng X, Rejto PA, Kan JL, Christensen JG, Pavlicek A.

Mol Cancer Ther. 2012 Mar;11(3):710-9. doi: 10.1158/1535-7163.MCT-11-0184. Epub 2012 Jan 5.

14.

PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity.

Yuan J, Mehta PP, Yin MJ, Sun S, Zou A, Chen J, Rafidi K, Feng Z, Nickel J, Engebretsen J, Hallin J, Blasina A, Zhang E, Nguyen L, Sun M, Vogt PK, McHarg A, Cheng H, Christensen JG, Kan JL, Bagrodia S.

Mol Cancer Ther. 2011 Nov;10(11):2189-99. doi: 10.1158/1535-7163.MCT-11-0185. Epub 2011 Jul 12.

15.

Inducible expression of TGFβ, snail and Zeb1 recapitulates EMT in vitro and in vivo in a NSCLC model.

Argast GM, Krueger JS, Thomson S, Sujka-Kwok I, Carey K, Silva S, O'Connor M, Mercado P, Mulford IJ, Young GD, Sennello R, Wild R, Pachter JA, Kan JL, Haley J, Rosenfeld-Franklin M, Epstein DM.

Clin Exp Metastasis. 2011 Oct;28(7):593-614. doi: 10.1007/s10585-011-9394-8. Epub 2011 Jun 4.

PMID:
21643654
16.

Cooperative signaling between oncostatin M, hepatocyte growth factor and transforming growth factor-β enhances epithelial to mesenchymal transition in lung and pancreatic tumor models.

Argast GM, Mercado P, Mulford IJ, O'Connor M, Keane DM, Shaaban S, Epstein DM, Pachter JA, Kan JL.

Cells Tissues Organs. 2011;193(1-2):114-32. doi: 10.1159/000320179. Epub 2010 Nov 2.

PMID:
21041998
17.

Knockdown of Ron kinase inhibits mutant phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma.

Wang J, Rajput A, Kan JL, Rose R, Liu XQ, Kuropatwinski K, Hauser J, Beko A, Dominquez I, Sharratt EA, Brattain L, Levea C, Sun FL, Keane DM, Gibson NW, Brattain MG.

J Biol Chem. 2009 Apr 17;284(16):10912-22. doi: 10.1074/jbc.M809551200. Epub 2009 Feb 18.

18.

Colon carcinoma cells harboring PIK3CA mutations display resistance to growth factor deprivation induced apoptosis.

Wang J, Kuropatwinski K, Hauser J, Rossi MR, Zhou Y, Conway A, Kan JL, Gibson NW, Willson JK, Cowell JK, Brattain MG.

Mol Cancer Ther. 2007 Mar;6(3):1143-50.

19.

3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agent.

Mulvihill MJ, Kan JL, Cooke A, Bhagwat S, Beck P, Bittner M, Cesario C, Keane D, Lazarescu V, Nigro A, Nillson C, Panicker B, Smith V, Srebernak M, Sun FL, O'Connor M, Russo S, Fischetti G, Vrkljan M, Winski S, Castelhano AL, Emerson D, Gibson NW.

Bioorg Med Chem Lett. 2006 May 15;16(10):2729-33. Epub 2006 Feb 28.

PMID:
16504501
20.

Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs).

Mulvihill MJ, Kan JL, Beck P, Bittner M, Cesario C, Cooke A, Keane DM, Nigro AI, Nillson C, Smith V, Srebernak M, Sun FL, Vrkljan M, Winski SL, Castelhano AL, Emerson D, Gibson N.

Bioorg Med Chem Lett. 2005 Mar 15;15(6):1669-73.

PMID:
15745819
21.
22.
23.
24.
26.
27.

Recognition of unusual DNA structures by human DNA (cytosine-5)methyltransferase.

Smith SS, Kan JL, Baker DJ, Kaplan BE, Dembek P.

J Mol Biol. 1991 Jan 5;217(1):39-51.

PMID:
1988679
28.

Recognition of structural perturbations in DNA by human DNA(cytosine-5)methyltransferase.

Baker DJ, Kan JL, Smith SS.

Gene. 1988 Dec 25;74(1):207-10. No abstract available.

PMID:
3248725

Supplemental Content

Support Center